HRP20221327T1 - Niraparib, abirateron acetat i prednizon za liječenje raka prostate - Google Patents
Niraparib, abirateron acetat i prednizon za liječenje raka prostate Download PDFInfo
- Publication number
- HRP20221327T1 HRP20221327T1 HRP20221327TT HRP20221327T HRP20221327T1 HR P20221327 T1 HRP20221327 T1 HR P20221327T1 HR P20221327T T HRP20221327T T HR P20221327TT HR P20221327 T HRP20221327 T HR P20221327T HR P20221327 T1 HRP20221327 T1 HR P20221327T1
- Authority
- HR
- Croatia
- Prior art keywords
- niraparib
- prednisone
- abiraterone acetate
- day
- patient
- Prior art date
Links
- PCHKPVIQAHNQLW-CQSZACIVSA-N niraparib Chemical compound N1=C2C(C(=O)N)=CC=CC2=CN1C(C=C1)=CC=C1[C@@H]1CCCNC1 PCHKPVIQAHNQLW-CQSZACIVSA-N 0.000 title claims 30
- 229950011068 niraparib Drugs 0.000 title claims 30
- 229960004103 abiraterone acetate Drugs 0.000 title claims 29
- UVIQSJCZCSLXRZ-UBUQANBQSA-N abiraterone acetate Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CC[C@@H](CC4=CC[C@H]31)OC(=O)C)C=C2C1=CC=CN=C1 UVIQSJCZCSLXRZ-UBUQANBQSA-N 0.000 title claims 29
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 title claims 25
- 229960004618 prednisone Drugs 0.000 title claims 25
- 206010060862 Prostate cancer Diseases 0.000 title claims 6
- 208000000236 Prostatic Neoplasms Diseases 0.000 title claims 6
- 238000002360 preparation method Methods 0.000 claims 7
- 229940123237 Taxane Drugs 0.000 claims 1
- 239000003098 androgen Substances 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 239000006186 oral dosage form Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 238000002626 targeted therapy Methods 0.000 claims 1
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Claims (15)
1. Niraparib, abirateron acetat i prednizon, naznačeni time, da su za uporabu u postupku liječenja raka prostate, koji obuhvaća davanje pacijentu kojemu je to potrebno, terapijski učinkovite količine nirapariba, terapijski učinkovite količine abirateron acetata i terapijski učinkovite količine prednizona.
2. Niraparib, abirateron acetat i prednizon, za uporabu prema patentnom zahtjevu 1, naznačeni time, da rak prostate je hormonski osjetljiv rak prostate ili rak prostate otporan na kastraciju.
3. Niraparib, abirateron acetat i prednizon, za uporabu prema patentnom zahtjevu 1 ili 2, naznačeni time, da se niraparib daje u zasebnom pripravku od abirateron acetata, time, da se niraparib daje u zasebnom pripravku od abirateron acetata i prednizona, time, da se prednizon daje u zasebnom pripravku od nirapariba i abirateron acetata, ili time, da se svaki od nirapariba, abirateron acetata i prednizona, daje u zasebnim pripravcima.
4. Niraparib, abirateron acetat i prednizon, za uporabu prema bilo kojem od prethodnih patentnih zahtjeva, naznačeni time, da se svaki od nirapariba i abirateron acetata daje pacijentu jednom dnevno.
5. Niraparib, abirateron acetat i prednizon, za uporabu prema bilo kojem od prethodnih patentnih zahtjeva, naznačeni time, da se uključuje davanje pacijentu oko 500 do oko 1500 mg/dan, oko 600 do oko 1300 mg/dan, ili oko 900 do oko 1100 mg/dan abirateron acetata.
6. Niraparib, abirateron acetat i prednizon, za uporabu prema patentnom zahtjevu 5, naznačeni time, da se uključuje davanje pacijentu oko 1000 mg/dan ili oko 500 mg/dan abirateron acetata.
7. Niraparib, abirateron acetat i prednizon, za uporabu prema bilo kojem od patentnih zahtjeva 1 do 5, naznačeni time, da se uključuje davanje pacijentu oko 30 do oko 400 mg/dan, oko 100 do oko 300 mg/dan, ili oko 175 do oko 225 mg/dan nirapariba.
8. Niraparib, abirateron acetat i prednizon, za uporabu prema patentnom zahtjevu 6, naznačeni time, da se uključuje davanje pacijentu oko 200 mg/dan nirapariba.
9. Niraparib, abirateron acetat i prednizon, za uporabu prema bilo kojem od patentnih zahtjeva 1 do 4 i 7, naznačeni time, da se uključuje davanje pacijentu oko 1 do oko 25 mg/dan, oko 5 do oko 15 mg/dan, ili oko 9 do oko 11 mg/dan prednizona.
10. Niraparib, abirateron acetat i prednizon, za uporabu prema patentnom zahtjevu 8, naznačeni time, da se uključuje davanje pacijentu oko 10 mg/dan, ili oko 5 mg/dan prednizona.
11. Niraparib, abirateron acetat i prednizon, za uporabu prema bilo kojem od prethodnih patentnih zahtjeva, naznačeni time, da se uključuje davanje pacijentu nirapariba i abirateron acetata jednom dnevno u vremenskom periodu od više dana, i povećavanje doze jednoga ili oba od nirapariba i abirateron acetata, najmanje jednom u datom vremenskom periodu, primjerice, pri čemu se doziranje nirapariba povećava najmanje jednom u datom vremenskom periodu, te se opcionalno nadalje uključuje davanje prednizona pacijentu dva puta dnevno u vremenskom periodu od više dana, i povećavanje doze prednizona najmanje jednom u datom vremenskom periodu.
12. Niraparib, abirateron acetat i prednizon, za uporabu prema bilo kojem od prethodnih patentnih zahtjeva, naznačeni time, da se uključuje oralno davanje pacijentu nirapariba, abirateron acetata i prednizona.
13. Niraparib, abirateron acetat i prednizon, za uporabu prema bilo kojem od prethodnih patentnih zahtjeva, naznačeni time, da je pacijent bio podvrgnut kemoterapiji na bazi taksana prije davanja prve doze nirapariba i abirateron acetata, i/ili je pacijent bio podvrgnut najmanje jednoj liniji ciljane terapije na androgeni receptor prije davanja prve doze nirapariba i abirateron acetata.
14. Farmaceutski pripravak, naznačen time, da sadrži niraparib, abirateron acetat i prednizon u ukupnoj količini koja se nalazi u većem broju oralnih oblika za doziranje, i koja je terapijski učinkovita za liječenje raka prostate kod ljudskog pacijenta.
15. Pripravak prema patentnom zahtjevu 14, naznačen time, da je navedeni pripravak konfiguriran za oralno davanje, i/ili time, da pripravak sadrži oko 100 do oko 350 mg nirapariba, oko 100 do oko 1500 mg abirateron acetata, i oko 2 do oko 15 mg prednizona.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762485164P | 2017-04-13 | 2017-04-13 | |
| PCT/US2018/026661 WO2018191141A1 (en) | 2017-04-13 | 2018-04-09 | Combination therapy for prostate cancer |
| EP18720895.4A EP3609497B1 (en) | 2017-04-13 | 2018-04-09 | Niraparib, abiraterone acetate and prednisone for treating prostate cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20221327T1 true HRP20221327T1 (hr) | 2023-03-17 |
Family
ID=62067858
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20221327TT HRP20221327T1 (hr) | 2017-04-13 | 2018-04-09 | Niraparib, abirateron acetat i prednizon za liječenje raka prostate |
Country Status (30)
| Country | Link |
|---|---|
| US (3) | US20180296574A1 (hr) |
| EP (3) | EP3609497B1 (hr) |
| JP (3) | JP7141408B2 (hr) |
| KR (1) | KR20190134718A (hr) |
| CN (1) | CN110753545A (hr) |
| AU (2) | AU2018251594A1 (hr) |
| BR (1) | BR112019021466A2 (hr) |
| CA (1) | CA3059562A1 (hr) |
| CL (1) | CL2019002871A1 (hr) |
| CO (1) | CO2019011591A2 (hr) |
| CR (1) | CR20190467A (hr) |
| DK (1) | DK3609497T3 (hr) |
| DO (1) | DOP2019000264A (hr) |
| EA (1) | EA201992430A1 (hr) |
| ES (1) | ES2931052T3 (hr) |
| HR (1) | HRP20221327T1 (hr) |
| HU (1) | HUE060460T2 (hr) |
| JO (1) | JOP20190244A1 (hr) |
| LT (1) | LT3609497T (hr) |
| MA (1) | MA48728B1 (hr) |
| MD (1) | MD3609497T2 (hr) |
| MX (2) | MX2019012296A (hr) |
| NI (1) | NI201900105A (hr) |
| PE (1) | PE20200444A1 (hr) |
| PH (1) | PH12019502317A1 (hr) |
| PL (1) | PL3609497T3 (hr) |
| PT (1) | PT3609497T (hr) |
| RS (1) | RS63832B1 (hr) |
| SG (1) | SG11201909552VA (hr) |
| WO (1) | WO2018191141A1 (hr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20240115925A (ko) | 2016-07-29 | 2024-07-26 | 얀센 파마슈티카 엔브이 | 전립선암의 치료 방법 |
| WO2020139339A1 (en) * | 2018-12-27 | 2020-07-02 | Constellation Pharmaceuticals, Inc. | Ezh2 and androgen receptor signaling inhibitors as tools for targeting prostate cancer |
| CN113546037A (zh) * | 2020-04-20 | 2021-10-26 | 鲁南制药集团股份有限公司 | 一种醋酸阿比特龙栓剂及其制备方法 |
| BR112022021732A2 (pt) * | 2020-05-08 | 2022-12-06 | Janssen Pharmaceutica Nv | Tratamentos de câncer de próstata com combinações de acetato de abiraterona e niraparibe |
| TWI828471B (zh) | 2021-12-15 | 2024-01-01 | 大陸商湖南慧澤生物醫藥科技有限公司 | 醋酸阿比特龍的自微乳組合物和應用 |
| CN114306236B (zh) * | 2021-12-15 | 2022-10-21 | 湖南慧泽生物医药科技有限公司 | 用于负载醋酸阿比特龙的自微乳体系及组合物和应用 |
| WO2023194525A1 (en) * | 2022-04-07 | 2023-10-12 | Astrazeneca Ab | Combination therapy for treating cancer |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080051380A1 (en) * | 2006-08-25 | 2008-02-28 | Auerbach Alan H | Methods and compositions for treating cancer |
| KR20150108946A (ko) * | 2006-08-25 | 2015-09-30 | 코우가 바이오테크놀로지, 인크. | 암을 치료하기 위한 방법 및 조성물 |
| SI2805945T1 (sl) | 2007-01-10 | 2019-09-30 | Msd Italia S.R.L. | Amid substituirani indazoli, kot inhibitorji poli(ADP-riboza)polimeraze(PARP) |
| US8436185B2 (en) | 2008-01-08 | 2013-05-07 | Merck Sharp & Dohme Corp. | Pharmaceutically acceptable salts of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide |
| WO2012009475A1 (en) * | 2010-07-14 | 2012-01-19 | Oregon Health & Science University | Methods of treating cancer with inhibition of lysine-specific demethylase 1 |
| WO2014089324A1 (en) * | 2012-12-07 | 2014-06-12 | Calitor Sciences, Llc | Substituted cyclic compounds and methods of use |
-
2017
- 2017-06-16 JO JOP/2019/0244A patent/JOP20190244A1/ar unknown
-
2018
- 2018-04-09 HU HUE18720895A patent/HUE060460T2/hu unknown
- 2018-04-09 LT LTEPPCT/US2018/026661T patent/LT3609497T/lt unknown
- 2018-04-09 JP JP2019555852A patent/JP7141408B2/ja active Active
- 2018-04-09 PL PL18720895.4T patent/PL3609497T3/pl unknown
- 2018-04-09 MA MA48728A patent/MA48728B1/fr unknown
- 2018-04-09 KR KR1020197032257A patent/KR20190134718A/ko not_active Application Discontinuation
- 2018-04-09 EP EP18720895.4A patent/EP3609497B1/en active Active
- 2018-04-09 EP EP22200801.3A patent/EP4176878A1/en active Pending
- 2018-04-09 RS RS20221127A patent/RS63832B1/sr unknown
- 2018-04-09 AU AU2018251594A patent/AU2018251594A1/en not_active Abandoned
- 2018-04-09 ES ES18720895T patent/ES2931052T3/es active Active
- 2018-04-09 CN CN201880039365.1A patent/CN110753545A/zh active Pending
- 2018-04-09 MX MX2019012296A patent/MX2019012296A/es unknown
- 2018-04-09 PE PE2019002030A patent/PE20200444A1/es unknown
- 2018-04-09 WO PCT/US2018/026661 patent/WO2018191141A1/en active Application Filing
- 2018-04-09 DK DK18720895.4T patent/DK3609497T3/da active
- 2018-04-09 PT PT187208954T patent/PT3609497T/pt unknown
- 2018-04-09 EA EA201992430A patent/EA201992430A1/ru unknown
- 2018-04-09 EP EP22200882.3A patent/EP4176879A1/en not_active Withdrawn
- 2018-04-09 HR HRP20221327TT patent/HRP20221327T1/hr unknown
- 2018-04-09 CA CA3059562A patent/CA3059562A1/en active Pending
- 2018-04-09 BR BR112019021466-6A patent/BR112019021466A2/pt active Search and Examination
- 2018-04-09 CR CR20190467A patent/CR20190467A/es unknown
- 2018-04-09 MD MDE20200190T patent/MD3609497T2/ro unknown
- 2018-04-09 SG SG11201909552V patent/SG11201909552VA/en unknown
- 2018-04-11 US US15/950,707 patent/US20180296574A1/en active Pending
-
2019
- 2019-10-08 CL CL2019002871A patent/CL2019002871A1/es unknown
- 2019-10-09 NI NI201900105A patent/NI201900105A/es unknown
- 2019-10-10 PH PH12019502317A patent/PH12019502317A1/en unknown
- 2019-10-14 MX MX2023009569A patent/MX2023009569A/es unknown
- 2019-10-14 DO DO2019000264A patent/DOP2019000264A/es unknown
- 2019-10-18 CO CONC2019/0011591A patent/CO2019011591A2/es unknown
-
2022
- 2022-02-25 US US17/680,553 patent/US20220175801A1/en not_active Abandoned
- 2022-07-22 JP JP2022117192A patent/JP7407880B2/ja active Active
-
2023
- 2023-11-20 JP JP2023196574A patent/JP2024023344A/ja active Pending
-
2024
- 2024-02-01 US US18/429,778 patent/US20240245710A1/en active Pending
- 2024-04-11 AU AU2024202346A patent/AU2024202346A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20221327T1 (hr) | Niraparib, abirateron acetat i prednizon za liječenje raka prostate | |
| Yan et al. | Natural product andrographolide alleviated APAP-induced liver fibrosis by activating Nrf2 antioxidant pathway | |
| HRP20200991T1 (hr) | Modulator androgenog receptora u kombinaciji s abirateron acetatom i prednizonom za liječenje karcinoma prostate | |
| HRP20210670T1 (hr) | Pripravci za liječenje raka | |
| JP2020516646A5 (hr) | ||
| JP2018111728A5 (hr) | ||
| HRP20170056T2 (hr) | Terapija male učestalosti glatiramer acetatom | |
| Jurgens et al. | The use of conventional disease-modifying anti-rheumatic drugs in established RA | |
| JP2010501576A5 (hr) | ||
| HRP20210572T1 (hr) | Kombinacijsko liječenje raka | |
| JP2012082215A5 (hr) | ||
| JP2017510579A5 (hr) | ||
| JP2015038135A5 (hr) | ||
| Spies et al. | Prednisone chronotherapy | |
| JP2019530706A5 (hr) | ||
| HRP20201307T1 (hr) | Upotreba reslizumaba za liječenje umjerene do ozbiljne eozinofilne astme | |
| JP2015500822A5 (hr) | ||
| BR112012030641B8 (pt) | Usos e composições para terapia farmacêutica oral | |
| Alten et al. | Hypothalamic-pituitary-adrenal axis function in patients with rheumatoid arthritis treated with different glucocorticoid approaches | |
| HRP20192189T1 (hr) | Doziranja i terapijske primjene l-4-klorokinurenina | |
| Montiel-Ruiz et al. | Synergistic interactions between the antinociceptive effect of Rhodiola rosea extract and B vitamins in the mouse formalin test | |
| HRP20201315T1 (hr) | Pripravak koji sadrži hidrokortizon | |
| JP2017524721A5 (hr) | ||
| JP2021502347A5 (hr) | ||
| WO2022046452A3 (en) | Nanoparticulate system for delivery of pain relief agents |